ANI receives FDA nod for generic EC-Naprosyn

ANI has obtained the Food and Drug Administration’s green light for Naproxen Delayed-Release Tablets, which is the generic of EC-Naprosyn.

The medication is a type of nonsteroidal anti-inflammatory drug. 

"We are pleased to announce the first cycle FDA approval and commercialization of Naproxen Delayed-Release Tablets. ANI remains committed to driving growth through superior new product launch execution, in keeping with our purpose of ‘Serving Patients, Improving Lives,’” said Nikhil Lalwani, president and CEO of ANI.

[Read more: ANI releases Kionex Suspension]

Naproxen Delayed-Release Tablets have a market value of approximately $36.7 million, per  April 2024 IQVIA data.

[Read more: ANI obtains FDA OK for generic Divigel]